IRIS
MATERA, Maria Gabriella
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 18.846
NA - Nord America 12.607
AS - Asia 8.517
SA - Sud America 1.541
Continente sconosciuto - Info sul continente non disponibili 406
AF - Africa 110
OC - Oceania 11
Totale 42.038
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.309
RU - Federazione Russa 11.394
SG - Singapore 3.441
IE - Irlanda 1.961
CN - Cina 1.610
HK - Hong Kong 1.544
IT - Italia 1.489
BR - Brasile 1.301
UA - Ucraina 1.122
GB - Regno Unito 939
VN - Vietnam 850
DE - Germania 768
FI - Finlandia 289
KR - Corea 280
FR - Francia 270
GR - Grecia 223
SE - Svezia 192
TR - Turchia 185
IN - India 184
CA - Canada 116
JP - Giappone 107
AR - Argentina 81
MX - Messico 56
BD - Bangladesh 53
ID - Indonesia 47
IQ - Iraq 38
EC - Ecuador 37
CO - Colombia 33
NL - Olanda 32
CR - Costa Rica 27
BE - Belgio 26
ES - Italia 25
CL - Cile 24
ZA - Sudafrica 24
UZ - Uzbekistan 21
VE - Venezuela 20
PK - Pakistan 19
MA - Marocco 18
PY - Paraguay 18
AT - Austria 17
IL - Israele 17
JM - Giamaica 17
PE - Perù 17
PL - Polonia 15
TT - Trinidad e Tobago 14
DZ - Algeria 13
MY - Malesia 13
HN - Honduras 12
EE - Estonia 11
MD - Moldavia 11
AE - Emirati Arabi Uniti 10
EG - Egitto 10
TH - Thailandia 10
TW - Taiwan 10
KE - Kenya 9
NI - Nicaragua 9
PH - Filippine 9
RO - Romania 9
SC - Seychelles 9
AU - Australia 8
BB - Barbados 8
EU - Europa 8
IR - Iran 8
SA - Arabia Saudita 8
TN - Tunisia 8
BG - Bulgaria 7
DO - Repubblica Dominicana 7
ET - Etiopia 7
NP - Nepal 7
AL - Albania 6
CH - Svizzera 6
CZ - Repubblica Ceca 6
PR - Porto Rico 6
CI - Costa d'Avorio 5
GP - Guadalupe 5
GT - Guatemala 5
LB - Libano 5
PT - Portogallo 5
UY - Uruguay 5
AZ - Azerbaigian 4
OM - Oman 4
PS - Palestinian Territory 4
SV - El Salvador 4
BH - Bahrain 3
BO - Bolivia 3
BS - Bahamas 3
BY - Bielorussia 3
BZ - Belize 3
HR - Croazia 3
JO - Giordania 3
KG - Kirghizistan 3
KZ - Kazakistan 3
LT - Lituania 3
NZ - Nuova Zelanda 3
QA - Qatar 3
SK - Slovacchia (Repubblica Slovacca) 3
AP - ???statistics.table.value.countryCode.AP??? 2
GE - Georgia 2
GY - Guiana 2
PA - Panama 2
Totale 41.608
Salva come PNG Salva come JPEG
Città #
Moscow 4.002
Dublin 1.955
Jacksonville 1.718
Hong Kong 1.525
Santa Clara 1.463
Singapore 1.343
San Jose 1.251
Ashburn 1.067
Council Bluffs 913
Chandler 757
Princeton 409
Medford 327
Ho Chi Minh City 276
Seoul 264
Milan 247
Bremen 225
Hefei 211
Hanoi 203
Roxbury 188
Boardman 183
Beijing 179
San Mateo 158
The Dalles 150
Wilmington 140
Bengaluru 139
Ann Arbor 102
Dallas 93
Woodbridge 87
Naples 82
Cambridge 77
Des Moines 74
São Paulo 73
New York 68
Rome 64
Los Angeles 63
Miano 62
Da Nang 59
North Bergen 51
Düsseldorf 49
Atlanta 44
Caserta 42
Haiphong 42
Rio de Janeiro 40
Orem 39
Shanghai 37
Munich 34
Norwalk 34
Jinan 33
Brasília 28
Montreal 26
Nanjing 25
Brussels 24
Frankfurt am Main 24
Tokyo 24
Curitiba 23
Hải Dương 23
Zhengzhou 23
Biên Hòa 22
Chicago 22
Guangzhou 22
Phoenix 22
Tashkent 21
Houston 20
Memphis 20
Belo Horizonte 19
Brooklyn 19
Falkenstein 19
Changsha 18
Guarulhos 18
Hebei 18
Napoli 18
San José 18
Bari 17
Nuremberg 17
Toronto 17
Campinas 16
Florence 16
London 16
Mexico City 16
Mountain View 16
Porto Alegre 16
San Potito Sannitico 16
Shenyang 16
Dhaka 15
Redwood City 15
Salvador 15
San Francisco 15
San Marcellino 15
Turku 15
Shenzhen 14
Baghdad 13
Columbus 13
Denver 13
Goiânia 13
Miami 13
Osasco 13
Auburn Hills 12
Haikou 12
Kingston 12
Seattle 12
Totale 21.567
Salva come PNG Salva come JPEG
Nome #
Farmaci dell’Apparato Respiratorio: Regolazione del tono broncomotore. 405
Sistema purinergico. 372
The effect of N-acetylcysteine on biofilms: Implications for the treatment of respiratory tract infections 266
Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: A comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine 204
“COPDCoRi: applicazione non invasiva per la stima e la previsione del rischio di patologia coronarica nei pazienti affetti da broncopneumopatia cronica ostruttiva (BPCO)”. 196
Antiflammins suppress the A23187- and arachidonic acid-dependent chloride secretion in rabbit distal colonic mucosa 190
Effects of chronic administration of β-blockers on airway responsiveness in a murine model of heart failure. 188
Effects of chronic treatment with the new ultra-long-acting β2 -adrenoceptor agonist indacaterol alone or in combination with the β1 -adrenoceptor blocker metoprolol on cardiac remodelling. 182
10. Aclidinium bromide/formoterol fumarate fixed-dose combination for the treatment of chronic obstructive pulmonary disease. 180
Aclidinium bromide inhalation powder for the long-term, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease including chronic bronchitis and emphysema 180
ACE2: The Major Cell Entry Receptor for SARS-CoV-2 178
Amminoacidi eccitatori e regolazione centrale della funzione cardiovascolare: contributi sperimentali. 174
Brain natriuretic peptide : much more than a biomarker 173
Animal models of chronic obstructive pulmonary disease and their role in drug discovery and development: a critical review 166
Severe respiratory SARS-CoV2 infection: Does ACE2 receptor matter? 164
Effect of hyperbaric oxygen therapy in experimental subcutaneous and pulmonary infections due to Pseudomonas aeruginosa 162
A single high dose of formoterol is as effective as the same dose administered in a cumulative manner in patients with acute exacerbation of COPD 159
A comparison of sensory nerve function in human, guinea-pig, rabbit and marmoset airways 158
1. New developments in the combination treatment of COPD: focus on umeclidinium/vilanterol. 158
A comparison of the bronchodilating effects of salmeterol, salbutamol and ipratropium bromide in patients with chronic obstructive pulmonary disease 155
Sirtuins and Cellular Senescence in Patients with Idiopathic Pulmonary Fibrosis and Systemic Autoimmune Disorders 154
Calcium dependence of the evoked arginine vasopressin release by electrical stimulation and by L-glutamate 154
Acute effects of higher than customary doses of salmeterol and salbutamol in patients with acute exacerbation of COPD. 152
Assessing the viability of long-acting β(2)-agonists in paediatric asthma patients: a pharmacokinetic/pharmacodynamic perspective. 152
Characterization of adenosine receptors involved in adenosine-induced bronchoconstriction in allergic rabbits 150
A combination with clinical recommended dosages of salmeterol and ipratropium is not more effective than salmeterol alone in patients with chronic obstructive pulmonary disease 149
Aclidinium bromide for the treatment of chronic obstructive pulmonary disease. 149
Protein Prenylation Contributes to the Effects of LPS on EFS-Induced Responses in Human Isolated Bronchi 149
An update on the currently available and emerging synthetic pharmacotherapy for uncontrolled asthma 147
5-HT modifiers as a potential treatment of asthma 146
A comparison of bronchodilating effects of salmeterol and oxitropium bromide in stable chronic obstructive pulmonary disease 145
Excitatory amino acids and cardiovascular apparatus: experimental studies on conscious rats with L-glutamate, N-methyl-D-aspartate, kainate and quisqualate 142
Farmaci del sistema cardiovascolare, del sangue e del rene 141
A review of the pharmacokinetics of M3 muscarinic receptor antagonists used for the treatment of asthma 141
Effects of hyperbaric oxygen exposure on non-adrenergic non-cholinergic responses of rat trachea 140
A safety comparison of LABA+LAMA vs LABA+ICS combination therapy for COPD 140
[The therapeutic prospects of ischemic cardiopathy] 140
Contribution of sensory nerves to LPS-induced hyperresponsiveness of human isolated bronchi. 139
The anti-proliferative effects of adiponectin on human lung adenocarcinoma A549 cells and oxidative stress involvement 139
Pulmonary penetration of dirithromycin in patients suffering from acute exacerbation of chronic bronchitis 137
Research on heterocyclic compounds. XIV - Imidazothiazole and imidazobenzothiazole derivatives: synthesis and antiinflammatory activity 137
Role of 5-hydroxytryptamine in mediating adenosine-induced airway contraction 137
K+ channels and guinea-pig trachea: a possible functional modulation by GABAB receptors 137
. Brain natriuretic peptide modulates calcium homeostasis and epidermal growth factor receptor gene signalling in asthmatic airways smooth muscle cells. 136
Drug-Drug Interactions and Synergy: From Pharmacological Models to Clinical Application 134
Chronic obstructive pulmonary disease and coronary disease: COPDCoRi, a simple and effective algorithm for predicting the risk of coronary artery disease in COPD patients. 133
Evidence of muscarinic receptor subtypes in airway smooth muscle of normal volunteers and of chronic obstructive pulmonary disease patients 133
A systematic review with meta-analysis of dual bronchodilation with LAMA/LABA for the treatment of stable COPD 133
characterization of the Pharmacological interaction between aclidinium bromide and formoterol fumarate on human isolated bronchi. 132
Ions and intracellular mechanisms involved in the effects of L-glutamate on arginine vasopressin release: in vitro researches on rat neurohypophysis 132
Effects of RO 5-4864 and PK 11195 on guinea pig trachea 132
Umeclidinium bromide + vilanterol for the treatment of chronic obstructive pulmonary disease. 132
N-Acetylcysteine protects human bronchi by modulating the release of neurokinin A in an ex vivo model of COPD exacerbation. 132
Effects of in vitro 5-HT1 receptor activation in guinea pig trachea 131
Bioavailability of timolol and aceclidine after ocular instillation in the rabbit 131
Adding a LAMA to ICS/LABA therapy: a meta-analysis of triple therapy in COPD 131
The additive effect of theophylline on a combination of formoterol and tiotropium in stable COPD: a pilot study 130
Pharmacological characterization of the interaction between the dual phosphodiesterase (PDE) 3/4 inhibitor RPL554 and glycopyrronium on human isolated bronchi and small airways. 130
Flomoxef, a new oxacephem antibiotic, does not cause hemostatic defects 130
A potential role of triple therapy for asthma patients 130
N-acetylcysteine in COPD may be beneficial, but for whom? 129
A long-term clinical trial on the efficacy and safety profile of doxofylline in Asthma: The LESDA study 129
Treatment of COPD: moving beyond the lungs. 128
Immune checkpoint inhibitors: a new landscape for extensive stage small cell lung cancer treatment 128
Pharmacokinetic/pharmacodynamic drug evaluation of benralizumab for the treatment of asthma. 127
Prenatal and postnatal antimony exposure in rats: effect on vasomotor reactivity development of pups 126
Prenatal and postnatal vanadium exposure in rats: effect on vasomotor reactivity development of pups 126
Brain Natriuretic Peptide Protects Against Hyperreactivity of Human Asthmatic Airway Smooth Muscle via an Epithelial Cell Dependent Mechanism. 125
Treating systemic effects of COPD. 125
Intraulmonary penetration of antimicrobials and implications in the treatment of lower respiratory tract infections. 125
Safety Considerations with Dual Bronchodilator Therapy in COPD: An Update 124
Evidence for non-adrenergic non-cholinergic contractile responses in bovine and swine trachea 124
Advances in the Pharmacological Management of Pediatric Acute Respiratory Distress Syndrome 124
Functional role of nitric oxide in guinea pig tracheal epithelium 123
Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis 123
The burden of obesity in asthma and COPD: Role of adiponectin 122
Pulmonary concentrations of dirithromycin and erythromycin during acute exacerbation of mild chronic obstructive pulmonary disease 121
Terapie per i disordini labirintici: effetti e riflessi sulla pressione arteriosa 121
The ongoing challenge of prevention of pertussis in infants: what’s new in 2024? 120
Current pharmacotherapeutic options for pediatric lower respiratory tract infections with a focus on antimicrobial agents 120
Tremor and β(2)-adrenergic agents: is it a real clinical problem? 119
Farmaci per il trattamento delle aritmie cardiache. 119
Impact of erdosteine on chronic bronchitis and COPD: A meta-analysis 119
Pharmacological treatment and current controversies in COPD 118
Translational Study Searching for Synergy between Glycopyrronium and Indacaterol. 118
Multifaceted activity of N-acetyl-l-cysteine in chronic obstructive pulmonary disease 118
Bronchodilator reversibility testing in post-COVID-19 patients undergoing pulmonary rehabilitation 118
Impact of biologics on lung hyperinflation in patients with severe asthma 117
A comprehensive overview of investigational elastase inhibitors for the treatment of acute respiratory distress syndrome 117
Bronchodilator therapy for chronic cough 117
Nitric oxide regulatory role in sensitized guinea pig trachea 117
I farmaci del sistema nervoso centrale 117
Farmaci per il trattamento della cardiopatia ischemica. 117
Effect of telenzepine, an M1-selective muscarinic receptor antagonist, in patients with nocturnal asthma 116
Ondansetron, an antagonist of 5-HT3 receptors, in the treatment of antineoplastic drug-induced nausea and vomiting in children 116
Role of 5-HT2 receptor subtypes in mediating adenosine-induced airway contraction 116
Possible functional modulation by acetylcholine of nitric oxide on guinea pig isolated trachea 116
Bronchodilator response to formoterol Turbuhaler in patients with COPD under regular treatment with formoterol Turbuhaler 115
Pulmonary disposition of lomefloxacin in patients with acute exacerbation of chronic obstructive pulmonary disease. A multiple-dose study 114
Pharmacological Characterization of Adenosine Receptors on Isolated Human Bronchi 113
Totale 14.396
Salva come PNG Salva come JPEG
Categoria #
all - tutte 149.825
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 149.825
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.725 0 0 0 42 688 7 25 47 59 70 185 602
2022/20233.445 411 47 36 234 440 248 7 178 1.694 17 53 80
2023/20241.395 103 34 35 138 551 59 36 33 14 21 85 286
2024/20255.490 34 33 57 154 874 615 551 446 657 1.411 394 264
2025/202619.242 848 800 1.035 1.260 1.277 10.682 1.152 704 772 368 234 110
2026/20274.594 207 738 1.663 1.986 0 0 0 0 0 0 0 0
Totale 42.038